KR20010040993A - 디뎀닌 화합물의 약제학적 제형 - Google Patents
디뎀닌 화합물의 약제학적 제형 Download PDFInfo
- Publication number
- KR20010040993A KR20010040993A KR1020007009012A KR20007009012A KR20010040993A KR 20010040993 A KR20010040993 A KR 20010040993A KR 1020007009012 A KR1020007009012 A KR 1020007009012A KR 20007009012 A KR20007009012 A KR 20007009012A KR 20010040993 A KR20010040993 A KR 20010040993A
- Authority
- KR
- South Korea
- Prior art keywords
- water
- didemnin
- alkanol
- pharmaceutical composition
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (11)
- 수용성 물질을 함유하는 냉동건조된 디뎀닌 제제 및 혼합 용매의 재구성 용액을 포함하는 디뎀닌 화합물의 약제학적 조성물.
- 제 1 항에 있어서, 상기 조성물은 항종양 치료로서 환자에게 투여할 목적으로 재구성됨을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물.
- 제 1 항 또는 제 2 항에 있어서, 상기 디뎀닌은 디뎀닌, 디히드로디뎀닌, 노르디뎀닌, 디뎀닌 동종체 및 디뎀닌 유사체로부터 선택됨을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물.
- 제 3 항에 있어서, 상기 디뎀닌 화합물은 아프리딘임을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물.
- 선행하는 청구항 중 어느 한 항에 있어서, 상기 재구성 용액은 알칸올/물 혼합물을 포함함을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물.
- 제 5 항에 있어서, 상기 재구성 용액은 비이온성 계면활성제를 포함함을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물.
- 제 6 항에 있어서, 상기 비이온 계면활성제는 상기 용액의 10 내지 25 vol%이고; 상기 알칸올은 에탄올이며 상기 용액의 10 내지 25 vol%이고; 그리고 상기 물은 상기 용액의 50 내지 80 vol%임을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물.
- 선행하는 청구항 중 어느 한 항에 있어서, 상기 제형은 수용성 부피 조정제를 함유하는 냉동건조된 디뎀닌 제제의 바이알, 및 비이온 계면활성제/에탄올/물의 전혼합물의 별도의 바이알을 포함하는 디뎀닌 화합물의 약제학적 조성물.
- 디뎀닌/수용성 첨가제/알칸올/물 혼합물을 냉동건조하여 냉동건조된 1차적인 성분을 얻고, 재구성 용액으로서 알칸올/물 혼합물을 분리적으로 얻는 것을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물의 제조방법.
- 제 9 항에 있어서, 상기 혼합물내의 알칸올은 t-부탄올임을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물의 제조방법.
- 제 9 항 또는 제 10 항에 있어서, 상기 알칸올/물 혼합물내의 알칸올의 양은 25 내지 60 vol%임을 특징으로 하는 디뎀닌 화합물의 약제학적 조성물의 제조방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9803448.1A GB9803448D0 (en) | 1998-02-18 | 1998-02-18 | Pharmaceutical formulation |
GB9803448.1 | 1998-02-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010040993A true KR20010040993A (ko) | 2001-05-15 |
KR100595597B1 KR100595597B1 (ko) | 2006-07-03 |
Family
ID=10827213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007009012A KR100595597B1 (ko) | 1998-02-18 | 1999-02-18 | 디뎀닌 화합물의 약제학적 제형 |
Country Status (17)
Country | Link |
---|---|
US (1) | US8420130B1 (ko) |
EP (1) | EP1054686B1 (ko) |
JP (2) | JP4536255B2 (ko) |
KR (1) | KR100595597B1 (ko) |
CN (1) | CN1170586C (ko) |
AT (1) | ATE217532T1 (ko) |
AU (1) | AU754073B2 (ko) |
BR (1) | BRPI9908088C1 (ko) |
CA (1) | CA2321116C (ko) |
DE (1) | DE69901487T2 (ko) |
DK (1) | DK1054686T3 (ko) |
ES (1) | ES2175940T3 (ko) |
GB (1) | GB9803448D0 (ko) |
HK (1) | HK1032538A1 (ko) |
IL (1) | IL137911A (ko) |
PT (1) | PT1054686E (ko) |
WO (1) | WO1999042125A1 (ko) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030148933A1 (en) | 1990-10-01 | 2003-08-07 | Pharma Mar S.A. | Derivatives of dehydrodidemnin B |
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
GB0002952D0 (en) | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
DE10008128A1 (de) * | 2000-02-22 | 2001-08-23 | Bayer Ag | Endoparasitizide Mittel |
UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
US7507766B2 (en) | 2000-10-12 | 2009-03-24 | Pharma Mar, S.A. | Treatment of cancers |
KR100834138B1 (ko) * | 2000-10-31 | 2008-06-02 | 파르마 마르, 에스.에이. | 카할라리드 에프 |
GB0304367D0 (en) | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
US7507708B2 (en) | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
DE602004016126D1 (de) * | 2003-03-12 | 2008-10-09 | Dana Farber Cancer Inst Inc | Aplidine zur behandlung von multiplem myelom |
RU2341283C2 (ru) | 2003-03-12 | 2008-12-20 | Фарма Мар, С.А. | Усовершенствованное лечение опухолей |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
CN100335495C (zh) * | 2006-01-23 | 2007-09-05 | 南方医科大学 | 一种海鞘多肽及其制备方法 |
HUE028055T2 (en) | 2006-02-28 | 2016-11-28 | Pharma Mar Sa | Improved treatment of myeloma multiplex |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
CN107837395A (zh) | 2011-02-09 | 2018-03-27 | 葛兰素史密斯克莱有限责任公司 | 冻干制剂 |
JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
US20230158104A1 (en) | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in autoimmune conditions |
WO2021175826A1 (en) | 2020-03-02 | 2021-09-10 | Pharma Mar, S.A. | Compounds for use in the treatment of coronavirus infection |
JP2023517194A (ja) | 2020-03-02 | 2023-04-24 | ファルマ、マール、ソシエダード、アノニマ | コロナウイルス感染の処置における組合せに使用するためのpld |
MX2022010921A (es) | 2020-03-02 | 2022-09-29 | Pharma Mar Sa | Compuestos para su uso en afecciones inflamatorias. |
CN114085272B (zh) * | 2022-01-10 | 2022-06-10 | 中山大学 | 一种isaridin类环酯肽衍生物及其制备方法和应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342744A (en) * | 1979-07-19 | 1982-08-03 | Lever Brothers Company | Hair treatment products |
JPS5781413A (en) * | 1980-09-12 | 1982-05-21 | Univ Illinois | Didemnin antibiotic |
US4950649A (en) * | 1980-09-12 | 1990-08-21 | University Of Illinois | Didemnins and nordidemnins |
DE3161556D1 (en) | 1980-09-12 | 1984-01-05 | Univ Illinois | Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them |
US4493796A (en) | 1980-09-12 | 1985-01-15 | Board Of Trustees, Univ. Of Ill. | Didemnins A, B, C, and derivatives thereof, as antiviral agents |
IT1153974B (it) | 1982-09-23 | 1987-01-21 | Erba Farmitalia | Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento |
US4948791A (en) | 1989-04-10 | 1990-08-14 | The Board Of Trustees Of The University Of Illinois | Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum |
GB8922026D0 (en) | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
DE4120327A1 (de) | 1991-06-20 | 1992-12-24 | Basf Ag | Neue peptide, ihre herstellung und verwendung |
FR2698543B1 (fr) * | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
IL109350A (en) * | 1993-05-12 | 2001-01-28 | Genentech Inc | Stable liquid preparations of gamma interferon |
US5462726A (en) | 1993-12-17 | 1995-10-31 | Bristol-Myers Squibb Company | Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents |
DE69431071T2 (de) * | 1993-12-29 | 2003-03-20 | Matrix Pharma | Zusammensetzung für lokale freigabe von zytostatika |
US5861439A (en) * | 1994-11-14 | 1999-01-19 | Alza Corporation | Method for enhanced electrotransport agent delivery |
ES2102322B1 (es) | 1995-07-13 | 1998-03-01 | Pharma Mar Sa | Procedimiento de preparacion de didemnina a. |
US6365597B1 (en) * | 1996-02-14 | 2002-04-02 | Aventis Pharmaceuticals Inc. | 4-aza steroids |
US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
ATE196844T1 (de) | 1996-05-22 | 2000-10-15 | Protarga Inc | Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten |
US6156724A (en) | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
DK0918693T3 (da) | 1996-07-03 | 2002-03-04 | Paxton C G Ltd | Beholdere |
CA2269881A1 (en) | 1996-10-24 | 1998-04-30 | The Board Of Trustees Of The University Of Illinois | Semi-synthetic studies toward didemnin analogues |
ATE245435T1 (de) | 1996-10-24 | 2003-08-15 | Univ Illinois | Totalsynthese des amino hip analogen von didemnin a |
US6034058A (en) | 1997-04-15 | 2000-03-07 | Rinehart; Kenneth L. | Semi-synthetic alanyl dilemnin analogs |
ES2321462T3 (es) * | 1997-05-07 | 2009-06-05 | Pharma Mar, S.A. | Uso de aplidina para el tratamiento de enfermedades cardiovasculares. |
GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
AU764807B2 (en) | 1998-07-30 | 2003-08-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
CA2373643A1 (en) | 1999-05-25 | 2000-11-30 | Point Therapeutics, Inc. | Anti-tumor comprising boroproline compounds |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
SI1229922T1 (sl) | 1999-11-15 | 2008-04-30 | Pharma Mar Sa | Zdravljenje raka z aplidinom |
AU2001251498A1 (en) | 2000-04-07 | 2001-10-23 | The Trustees Of The University Of Pennsylvania | Tamandarin and didemnin analogs and methods of making and using them |
US6509315B1 (en) | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
EP1325032A2 (en) | 2000-10-05 | 2003-07-09 | Immunex Corporation | Nectin polypeptides, polynucleotides, methods of making and use thereof |
MXPA03003230A (es) | 2000-10-12 | 2004-12-03 | Pharma Mar Sa | Tratamiento de canceres. |
WO2002032374A2 (en) | 2000-10-18 | 2002-04-25 | Immunex Corporation | Methods for treating il-18 mediated disorders |
EP1435991B1 (en) | 2001-10-19 | 2008-10-15 | Pharma Mar, S.A. | Use of aplidine for the treatment of pancreatic cancer |
RU2341283C2 (ru) | 2003-03-12 | 2008-12-20 | Фарма Мар, С.А. | Усовершенствованное лечение опухолей |
-
1998
- 1998-02-18 GB GBGB9803448.1A patent/GB9803448D0/en not_active Ceased
-
1999
- 1999-02-18 DE DE69901487T patent/DE69901487T2/de not_active Expired - Lifetime
- 1999-02-18 WO PCT/GB1999/000511 patent/WO1999042125A1/en active IP Right Grant
- 1999-02-18 EP EP99905091A patent/EP1054686B1/en not_active Expired - Lifetime
- 1999-02-18 AT AT99905091T patent/ATE217532T1/de active
- 1999-02-18 AU AU25389/99A patent/AU754073B2/en not_active Expired
- 1999-02-18 IL IL137911A patent/IL137911A/en not_active IP Right Cessation
- 1999-02-18 US US09/622,433 patent/US8420130B1/en not_active Expired - Fee Related
- 1999-02-18 CA CA002321116A patent/CA2321116C/en not_active Expired - Lifetime
- 1999-02-18 ES ES99905091T patent/ES2175940T3/es not_active Expired - Lifetime
- 1999-02-18 DK DK99905091T patent/DK1054686T3/da active
- 1999-02-18 KR KR1020007009012A patent/KR100595597B1/ko not_active IP Right Cessation
- 1999-02-18 JP JP2000532139A patent/JP4536255B2/ja not_active Expired - Lifetime
- 1999-02-18 PT PT99905091T patent/PT1054686E/pt unknown
- 1999-02-18 CN CNB998050393A patent/CN1170586C/zh not_active Expired - Lifetime
- 1999-02-18 BR BRPI9908088A patent/BRPI9908088C1/pt not_active IP Right Cessation
-
2001
- 2001-05-07 HK HK01103194A patent/HK1032538A1/xx not_active IP Right Cessation
-
2010
- 2010-03-08 JP JP2010050393A patent/JP2010163443A/ja not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HK1032538A1 (en) | 2001-07-27 |
BR9908088B1 (pt) | 2013-05-21 |
JP2010163443A (ja) | 2010-07-29 |
PT1054686E (pt) | 2002-09-30 |
GB9803448D0 (en) | 1998-04-15 |
WO1999042125A1 (en) | 1999-08-26 |
AU2538999A (en) | 1999-09-06 |
ATE217532T1 (de) | 2002-06-15 |
KR100595597B1 (ko) | 2006-07-03 |
IL137911A (en) | 2006-04-10 |
IL137911A0 (en) | 2001-10-31 |
DE69901487T2 (de) | 2002-12-19 |
JP4536255B2 (ja) | 2010-09-01 |
CA2321116A1 (en) | 1999-08-26 |
CA2321116C (en) | 2009-10-06 |
DK1054686T3 (da) | 2002-06-17 |
JP2002503704A (ja) | 2002-02-05 |
BRPI9908088B8 (pt) | 2017-03-07 |
DE69901487D1 (de) | 2002-06-20 |
BRPI9908088C1 (pt) | 2021-05-25 |
EP1054686A1 (en) | 2000-11-29 |
AU754073B2 (en) | 2002-11-07 |
CN1170586C (zh) | 2004-10-13 |
EP1054686B1 (en) | 2002-05-15 |
ES2175940T3 (es) | 2002-11-16 |
CN1330551A (zh) | 2002-01-09 |
US8420130B1 (en) | 2013-04-16 |
BR9908088A (pt) | 2000-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100595597B1 (ko) | 디뎀닌 화합물의 약제학적 제형 | |
AU764626B2 (en) | Pharmaceutical formulations of taxanes | |
JP5670335B2 (ja) | ベンダムスチン液体製剤 | |
JP4073503B2 (ja) | サイクロスポリンを含有する液体製剤とその調製方法 | |
JP4890732B2 (ja) | 癌治療用パクリタキセル・リポソーム組成物およびその製造方法 | |
US20120264817A1 (en) | Solubilized formulation of docetaxel without tween 80 | |
HU219477B (hu) | Rapamicint tartalmazó gyógyszerkészítmények intravénás injekciós adagoláshoz és eljárás előállításukra | |
HU217839B (hu) | Eljárások taxánszármazékokat tartalmazó új stabil gyógyszerkészítmények előállítására | |
FI94837B (fi) | Vesiliukoisia monoestereitä käytettäväksi farmakologisesti aktiivisten yhdisteiden kantajana ja farmaseuttisten apuaineiden liukoisuutta lisäävinä aineina | |
CN103974703A (zh) | 卡巴他赛制剂及其制备方法 | |
JPH09512261A (ja) | タキサン系の誘導体に基づく製薬組成物 | |
KR20030023875A (ko) | 투명 수용성 마취제 조성물 | |
WO2016059592A1 (en) | Stable injectable composition of peptide drugs and process for its preparation | |
HUT72738A (en) | New cyclosporine-containing pharmaceutical compositions for oral administration | |
HU199289B (en) | Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid | |
MXPA00008124A (en) | Pharmaceutical formulation of a didemnin compound | |
JP4624780B2 (ja) | 抗腫瘍活性を有するアントラセンジオン誘導体の注射用医薬組成物 | |
RU2236227C1 (ru) | Устойчивая фармацевтическая форма противоракового препарата | |
EP0236280B1 (en) | Injectable pharmaceutical formulations of active principles having general anaesthetic activity | |
JPH05124967A (ja) | 安定な静脈注射用総合ビタミン剤 | |
EP4025205A1 (en) | Cabazitaxel liquid formulations | |
JPS61207327A (ja) | 安定な混合ビタミン凍結乾燥製剤の製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130611 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140611 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150608 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160613 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170613 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180612 Year of fee payment: 13 |
|
EXPY | Expiration of term |